Market Research Logo
Region: Africa
Category: Life Sciences

Africa Life Sciences

(658 reports matching your criteria)
  • Cote d'Ivoire Pharmaceuticals & Healthcare Q1 2019

    ... experience growth through 2019 as production rampsup from several large new offshore fields. The monetisation of the country's gas resources remains largely contingent on plans for aFLNG export terminal, the timeline for which remains unclear. Read More

  • Zambia Pharmaceuticals & Healthcare Q1 2019

    ... will continue to deter innovativedrugmakers from involvement in the market. Still, opportunities for low-cost generic medicines remain plentiful, especially given thehigh burden of communicable conditions and the need to deal with outbreaks of viral diseases. Read More

  • Egypt Pharmaceuticals & Healthcare Q1 2019

    ... a new drug authority in Egypt will improve the medicine regulatory environment. Risks in the form ofdelays to implementation and macroeconomic challenges will persist. Pharmaceutical market growth remains on a robusttrajectory, outperforming the MENA average. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q1 2019

    ... through subsidised health insuranceschemes, and authorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground forsubstantial volume and value growth. On the other, this potential will mostly attract ... Read More

  • South Africa Pharmaceuticals & Healthcare Q1 2019

    ... status for innovative medicine launches. Nevertheless, South Africa’sconsiderable market size leaves it exposed to a number of external influences, both industry and macroeconomic related. Keydevelopments to watch over the near term include the impact of ... Read More

  • Egypt Medical Devices Q1 2019

    ... enormous potential for growth as the country has the largest population in the Arabworld. Improving political and economic fundamentals will support long-term market growth, following recent economic turbulenceand the massive depreciation of the Egyptian pound. Read More

  • Angola Pharmaceuticals & Healthcare Q1 2019

    ... will be driven the country’s growing disease burden andincreasing population. However, given the low levels of affordability, poor access to healthcare, and relatively young age of itspopulation, the market will mainly be suited to generic ... Read More

  • Healthcare Regulatory Environment in Kenya, Tanzania, and Ethiopia, 2018

    ... region has one of the highest burdens of disease in the world, such as HIV, malaria, and tuberculosis. On the other hand, there has been a growing trend of non-communicable diseases, such as cancers and ... Read More

  • Ghana Pharmaceuticals & Healthcare Q4 2018

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018

    ... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More

  • Algeria Pharmaceuticals & Healthcare Q1 2019

    ... and healthcare industries willcontinue to create investment opportunities, despite the slow progress in improving the regulatory environment. Despite sustaineddevelopment of local drug manufacturing capacity - which is in part driven by foreign direct investment and ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q1 2019

    ... Although the health system and pharmaceutical sector willcontinue to gradually develop, low spending per capita on medicine and a poor operating environment will continue to weigh onopportunities presented to drugmakers in the short term. The ... Read More

  • Uganda Pharmaceuticals & Healthcare Q4 2018

    ... remain dominant, while the government plans to localisedrug production to boost medicine sustainability. While the market has brighter long-term prospects, multinational drugmakerappetite will remain subdued despite the positive economic growth forecast over the coming years. Read More

  • Kenya Pharmaceuticals & Healthcare Q1 2019

    ... or distributors. Authorities are also investing in regulatoryimprovement initiatives, which will complement their efforts to achieve universal healthcare coverage. On the other hand, someforeign players may remain weary of committing to the market due to ... Read More

  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q4 2018

    ... multinational drugmakers are deterred by thechallenging macroeconomic environment. Achieving self-sufficiency in the sector will require currency regime reform; however, itremains unclear which new regime they will adopt. This creates uncertain conditions in Zimbabwe's pharmaceutical market ... Read More

  • Gabon Pharmaceuticals & Healthcare Q4 2018

    ... by factors including modest but growingpopulation numbers, high prevalence of infectious diseases and the growing burden of civilisation diseases. However, given thetight funding environment, most of the commercial opportunities remain limited to the generics sector. Read More

  • Tunisia Pharmaceuticals & Healthcare Q4 2018

    ... will challenge foreign investment into the sector.Highlighting the market's longer-term potential, some multinational drugmakers have shown their willingness to do business in thecountry, though the majority choose to operate indirectly to minimise the risks involved. Read More

  • Kenya Medical Devices Q4 2018

    ... the Kenyan shilling. The market will remain heavily reliant onimports due to domestic manufacturers focusing on basic consumables. The Equitable Division of Revenue Bill and ambitions ofachieving universal healthcare coverage will benefit medical device manufacturers. Read More

  • Sub-Saharan Africa Medical Devices Q4 2018

    ... GDP growth reading reflecting that it has entered into a technical recession,poses downside risks. The SSA market will remain heavily reliant on imports and international aid and funding, thereforemultinationals will continue to strengthen their presence. ... Read More

  • South Africa Medical Devices Q4 2018

    ... GDP growth reading reflecting that South Africa has entered into atechnical recession as the economy recorded two consecutive quarters of negative growth. However, the establishment of theSouth African Health Products Regulatory Authority (SAHPRA), which will ... Read More

  • Botswana Pharmaceuticals & Healthcare Q4 2018

    ... healthcare. Medicine sales will be limited by weakregulatory framework, a small pensionable population and a highly ruralised community. Despite a potential for growth in theunderdeveloped sector, multinational drugmakers will favour larger markets in the region ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q4 2018

    ... opportunities are supported by robust fundamentals such as a large market size and expandingpopulation. The majority of multinational drugmakers will continue to opt for an indirect presence as the business climate remainsdecidedly difficult in Nigeria. Read More

  • Mauritius Pharmaceuticals & Healthcare Q4 2018

    ... moderately greater spending power than its peers in Sub-SaharanAfrica, Mauritius’ per capita medicine expenditure will remain well below the purchasing power of developed markets. On the upside,the business environment will remain relatively strong, while Mauritius' ... Read More

  • Mozambique Pharmaceuticals & Healthcare Q4 2018

    ... diseases and improving the country'soverall health standing, poor regulatory framework and a fragmented healthcare system will limit patient access to qualitymedicines. Furthermore, ongoing political and economic risks cause us to view Mozambique as one of ... Read More

< prev 1 3 4 5 6 7 8 9 10